CORRESPONDENCE
Reply
Antonio D’Alessio,
Antonio D’Alessio
Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK
Department of Biomedical Sciences, Humanitas University, Milan, Italy
Search for more papers by this author Claudia Angela Maria Fulgenzi,
Claudia Angela Maria Fulgenzi
Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK
Division of Medical Oncology, Policlinico Universitario Campus Bio-Medico, Rome, Italy
Search for more papers by this author David J. Pinato,
Corresponding Author
David J. Pinato
Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK
Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy
Correspondence
David J. Pinato, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, W120HS London, UK.
Email: [email protected]
Search for more papers by this author
Antonio D’Alessio,
Antonio D’Alessio
Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK
Department of Biomedical Sciences, Humanitas University, Milan, Italy
Search for more papers by this author Claudia Angela Maria Fulgenzi,
Claudia Angela Maria Fulgenzi
Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK
Division of Medical Oncology, Policlinico Universitario Campus Bio-Medico, Rome, Italy
Search for more papers by this author David J. Pinato,
Corresponding Author
David J. Pinato
Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK
Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy
Correspondence
David J. Pinato, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, W120HS London, UK.
Email: [email protected]
Search for more papers by this author
First published: 03 May 2022
No abstract is available for this article.
CONFLICT OF INTEREST
AD received educational support for congress attendance and consultancy fees from Roche. DJP received lecture fees from ViiV Healthcare, EISAI, IPSEN and Bayer Healthcare and travel expenses from Bristol Myers Squibb and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, IPSEN, DaVolterra, Mursla and Astra Zeneca; received research funding (to institution) from Merck Sharp & Dome and Bristol Myers Squibb.
REFERENCES
- 1
D’Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, Felden J, Schulze K, et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study. Hepatology. 2022; 76: 1000–12.
- 2
Fang P, Hu JH, Cheng ZG, Liu ZF, Wang JL, Jiao SC. Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials. PLoS One. 2012; 7(12):e49717.
- 3
Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022; 76(4): 862–73.
- 4
Pinato DJ, Scotti L, Gennari A, Colomba-Blameble E, Dolly S, Loizidou A, et al. Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. Eur J Cancer. 2021; 150: 190–202.
- 5
Pinato DJ, Zambelli A, Aguilar-Company J, Bower M, Sng CCT, Salazar R, et al. Clinical portrait of the SARS-CoV-2 epidemic in European patients with cancer. Cancer Discov. 2020; 10(10): 1465–74.
- 6
Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28: iv119–42.
- 7
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020; 382(20): 1894–905.
